Impulse Dynamics announced that it raised more than $158 million in financing to support its heart failure treatment technology.
New institutional investors, including Sands Capital and Braidwell, led the financing. Returning investors Redmile, Perceptive and Alger, along with several prominent industry executives, also participated. This follows a $136 million raise last year.
Related: Saluda Medical raises $150M in Australian IPO to support neuromod tech
Marlton, New Jersey-based Impulse Dynamics said the funding helps to enhance commercialization and fuel its clinical and technology pipelines. Funding comes on the heels of a new CMS announcement issuing a national coverage determination (NCD) for CCM therapy.
Impulse Dynamics develops the Optimizer system, designed to deliver cardiac contractility modulation (CCM) therapy to the heart. It significantly improves heart contraction to allow more oxygen-rich blood to push out through the body.
“This support recognizes the evidence-based outcomes of CCM therapy, with over 12,000 patients implanted to date and opens the pathway to greater care for HF patients,” said Jason Spees, CEO, Impulse Dynamics. “As the NCD removes a significant barrier to access by providing coverage and reimbursement for a substantial patient population, this investment will help expand access to CCM therapy to more HF patients in need. Furthermore, it will accelerate the ongoing development and future commercialization of the CCM-D HF system, a single device designed to deliver CCM therapy for the treatment of HF symptoms along with life-saving, implantable cardioverter defibrillator (ICD) therapy.”
